Logo
x

Search

Subscribe Now

morphosys

MorphoSys and Incyte Presents Five-Year P-II Study (L-MIND) Results of Monjuvi (tafasitamab-cxix) for Relapsed or Refractory Diffuse Large B-Cell Lymphoma AACR 2023

MorphoSys and Incyte Presents Five-Year P-II Study (L-MIND) Results of Monjuvi (tafasitamab-cxix) for Relapsed or Refractory Diffu...

  • April 17, 2023
MorphoSys Reports the Completion of Patient Enrollment in P-III Study (MANIFEST-2) of Pelabresib for Myelofibrosis

MorphoSys Reports the Completion of Patient Enrollment in P-III Study (MANIFEST-2) of Pelabresib for Myelofibrosis

  • April 5, 2023
MorphoSys Reports (L-MIND) Study Results of Monjuvi (tafasitamab-cxix) for Relapsed or Refractory Diffuse Large B-Cell Lymphoma

MorphoSys Reports (L-MIND) Study Results of Monjuvi (tafasitamab-cxix) for Relapsed or Refractory Diffuse Large B-Cell Lymphoma

  • September 29, 2022
MorphoSys Entered into a License Agreements with HIBio to Develop and Commercialize Felzartamab and MOR21 for Autoimmune and Inflammatory Diseases

MorphoSys Entered into a License Agreements with HIBio to Develop and Commercialize Felzartamab and MOR21 for Autoimmune and Infla...

  • June 15, 2022
PharmaShots Weekly Snapshots (August 23, 27, 2021)

PharmaShots Weekly Snapshots (August 23, 27, 2021)

  • August 27, 2021
PharmaShots' Key Highlights of Second Quarter 2021

PharmaShots' Key Highlights of Second Quarter 2021

  • July 7, 2021
MorphoSys Reports the Completion of Patient Enrollment in P-III Study (MANIFEST-2) of Pelabresib for Myelofibrosis

    MorphoSys Reports the Completion of Patient Enrollment in P-III Study (MANIFEST-2) of Pelabresib for Myelofibrosis

    • April 5, 2023
    PharmaShots Weekly Snapshots (September 26 - 30, 2022)

      PharmaShots Weekly Snapshots (September 26 - 30, 2022)

      • September 30, 2022
      MorphoSys Reports (L-MIND) Study Results of Monjuvi (tafasitamab-cxix) for Relapsed or Refractory Diffuse Large B-Cell Lymphoma

        MorphoSys Reports (L-MIND) Study Results of Monjuvi (tafasitamab-cxix) for Relapsed or Refractory Diffuse Large B-Cell Lymphoma

        • September 29, 2022
        PharmaShots Weekly Snapshots (June 13– 17, 2022)

          PharmaShots Weekly Snapshots (June 13– 17, 2022)

          • June 17, 2022
          MorphoSys Entered into a License Agreements with HIBio to Develop and Commercialize Felzartamab and MOR21 for Autoimmune and Inflammatory Diseases

            MorphoSys Entered into a License Agreements with HIBio to Develop and Commercialize Felzartamab and MOR21 for Autoimmune and Infla...

            • June 15, 2022
            Top 20 Biopharma M&A of 2021 by Total Deal Value

              Top 20 Biopharma M&A of 2021 by Total Deal Value

              • January 20, 2022
              Image

              Incisive News in 3 Shots.

              Contact Us

              Our Information

              Follow Us

              Copyright © 2025 PharmaShots - All Rights Reserved.